Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Francisco, California. Kinnate Biopharma Inc. is a former subsidiary of Fount Therapeutics, LLC.
Earnings for Kinnate Biopharma Inc. (KNTE)
Earnings in 2023 (TTM): $-112,649,000
According to Kinnate Biopharma Inc.'s latest financial reports the company's current earnings (TTM) are $-112,649,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Kinnate Biopharma Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-112,649,000 | $-112,649,000 |
| 2022 | $-116,271,000 | $-114,021,000 |
| 2021 | $-89,763,000 | $-89,415,000 |
| 2020 | $-35,761,000 | $-35,433,000 |
| 2019 | $-11,969,000 | $-11,926,000 |
| 2018 | $-7,630,000 | $-7,630,000 |